Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics

使用新型α-突触核蛋白视网膜造影剂和人工智能辅助分析对非人类灵长类动物模型中的帕金森病和多系统萎缩进行鉴别诊断

• 批准号: 10323567
• 负责人: Stella Sarraf
• 金额: $ 207.76万
• 依托单位: AMYDIS DIAGNOSTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-23 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10323567
• 关键词: 3-Dimensional; Age-Years; Alzheimer' s Disease; Animal Model; Artificial Intelligence; Autopsy; Binding; Brain Injuries; Cadaver; Caring; Clinical; Clinical Trials; Cognitive; Computer software; Contrast Media; Data; Deposition; Detection; Development; Devices; Diagnosis; Diagnostic; Differential Diagnosis; Disease; Early Intervention; Elements; Eye; Fluorescence; Freeze Drying; Fundus; Goals; Human; Image; Individual; Kilogram; Lead; Lewy Body Dementia; Maps; Mission; Modeling; Monitor; Motor; Multiple System Atrophy; Neurodegenerative Disorders; Optical Coherence Tomography; Parkinson Disease; Pathologic; Pathology; Patients; Pharmaceutical Preparations; Physicians; Preventive treatment; Research; Resolution; Retina; Specialist; Structure; Symptoms; Testing; Therapeutic Intervention; Time; Tissues; Toxicogenetics; Toxicology; Tracer; Visual; Visualization; Work; age related; alpha synuclein; base; clinical practice; deep learning algorithm; design; disability; disease diagnosis; dopaminergic neuron; fluorescence imaging; graphical user interface; in vivo; mouse model; neuropsychiatry; nonhuman primate; novel; novel diagnostics; phototoxicology; programs; research clinical testing; retinal imaging; small molecule; synuclein; synucleinopathy; three dimensional structure; three-dimensional visualization; translation to humans

Project Summary Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, and a major cause of disability in individuals over 65 years of age. PD belongs to a spectrum of diseases termed the “synucleinopathies”, defined by the progressive aggregation of insoluble fibrillary a-synuclein, and includes other disorders such as multiple system atrophy and Lewy body dementia. Currently, there are no objective tests that can be used to definitively diagnose PD. In addition, differential diagnosis of synucleinopathies is very challenging and relies heavily on a physician's clinical evaluation. A critical goal in the field is to reliably identify synucleinopathies at early, asymptomatic stages of the disease, to allow the best chance for correct disease modifying or preventative treatments to be effective. This proposal aims to develop a small molecule fluorescent retinal contrast agent as a novel diagnostic for PD and other related synucleinopathies.

项目摘要 帕金森病（PD）是仅次于阿尔茨海默病的第二大常见神经退行性疾病， 也是导致65岁以上人群残疾的主要原因。PD属于一系列疾病， “突触核蛋白病”，定义为不溶性突触α-突触核蛋白的进行性聚集，包括 其他疾病如多系统萎缩和路易体痴呆。目前，还没有客观的测试 可以用来明确诊断帕金森病此外，突触核蛋白病的鉴别诊断是非常重要的。 具有挑战性，并严重依赖于医生的临床评估。该领域的一个关键目标是可靠地识别 突触核蛋白病在疾病的早期，无症状阶段，让最好的机会，正确的疾病 预防性治疗或预防性治疗有效。该提案旨在开发一种小分子荧光 视网膜造影剂作为PD和其他相关突触核蛋白病的新诊断剂。